Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 607 articles

Articles by Daniel Marsh

Mortgage Rates Hold Steady Near 6.3% as Key Economic Data Awaited
Economy

Mortgage Rates Hold Steady Near 6.3% as Key Economic Data Awaited

U.S. 30-year fixed mortgage rates remained near 6.28% early Tuesday, with markets focused on upcoming employment and inflation reports. Rocket Companies shares gained in premarket trading.

RKT SPY
Markets Await Retail Sales Data and Treasury Auction Amid Flat Futures
Markets

Markets Await Retail Sales Data and Treasury Auction Amid Flat Futures

U.S. stock futures held steady early Tuesday as investors braced for December retail sales figures and a $58 billion 3-year Treasury note auction. The Dow closed at a record high for a second consecutive session on Monday.

ON
Futures Inch Higher Ahead of Key Retail Sales, Earnings Reports
Markets

Futures Inch Higher Ahead of Key Retail Sales, Earnings Reports

U.S. stock futures edged up Tuesday as investors awaited crucial retail sales data and earnings from Coca-Cola and Ford. The S&P 500 futures rose 0.08%, while Dow futures added 45 points.

KO F META NVDA TSLA AAPL XLK
FTSE 100 Slips as BP Pauses Buybacks, StanChart Dives; AstraZeneca Gains
Markets

FTSE 100 Slips as BP Pauses Buybacks, StanChart Dives; AstraZeneca Gains

The FTSE 100 fell 0.4% early Tuesday, pressured by sharp declines in BP and Standard Chartered, while AstraZeneca climbed on a solid outlook. Sterling weakened amid political and rate uncertainty.

BP AZN BCS BCS GLD USO XLE XLF XLV
Dow Futures Edge Higher Ahead of Key Economic Data Releases
Markets

Dow Futures Edge Higher Ahead of Key Economic Data Releases

Dow Jones futures advanced slightly Tuesday as investors await retail sales figures, with payroll and inflation reports due later this week. Tech stocks led Monday's market recovery.

DIA SPY QQQ XLK MRNA MRK
Indian Equities Extend Gains on Foreign Inflows and Trade Optimism
Markets

Indian Equities Extend Gains on Foreign Inflows and Trade Optimism

Indian benchmarks rose for a third consecutive session, supported by foreign portfolio investments and optimism around a U.S. trade framework. Auto and metal stocks led the advance.

ASX 200 Ends Flat Amid AI Jitters; CSL Tumbles on CEO Exit
Markets

ASX 200 Ends Flat Amid AI Jitters; CSL Tumbles on CEO Exit

The S&P/ASX 200 closed virtually unchanged, dipping 2.7 points to 8,867.40. Insurance brokers slumped on AI competition fears, while CSL fell 5% after its CEO announced retirement.

CSL ASX XLF XLV
Transocean's $5.8B Valaris Acquisition Sparks Pre-Market Rally
Markets

Transocean's $5.8B Valaris Acquisition Sparks Pre-Market Rally

Transocean shares climbed 6% premarket after announcing an all-stock merger with Valaris, creating a combined fleet of 73 rigs with a $10 billion backlog.

RIG VAL
Valaris Shares Retreat in Premarket Following Transocean Acquisition-Driven Surge
Markets

Valaris Shares Retreat in Premarket Following Transocean Acquisition-Driven Surge

Valaris stock declined 2% in premarket trading after a 34% rally on news of an all-stock takeover by Transocean, valued at $82.12 per share.

RIG VAL
Abpro Holdings Soars 94% Premarket on Goldman Sachs Stake Disclosure
Markets

Abpro Holdings Soars 94% Premarket on Goldman Sachs Stake Disclosure

Abpro Holdings shares surged nearly 94% in premarket trading after a regulatory filing revealed Goldman Sachs holds a 6.8% passive stake in the biotech firm.

ABP
Quince Therapeutics Engages LifeSci for Strategic Review Amid Phase 3 Setback
Markets

Quince Therapeutics Engages LifeSci for Strategic Review Amid Phase 3 Setback

Quince Therapeutics shares fell 6.6% in premarket trading after hiring LifeSci Capital to explore strategic alternatives and debt restructuring, following a failed Phase 3 trial and board resignations.

QNCX
30-Year Mortgage Rates Hold Steady Near 6% as Fed Pause Extends
Economy

30-Year Mortgage Rates Hold Steady Near 6% as Fed Pause Extends

The average 30-year fixed mortgage rate remained at 5.99% this week, with limited movement as the Federal Reserve's next meeting is not until March. A survey indicates most buyers would reconsider plans if rates climb above 6%.

C